Unlabelled: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union's Horizon 2020 research and innovation programme and EFPIA.

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL / F. Koenig, C. Spiertz, D. Millar, S. Rodríguez-Navarro, N. Machín, A. Van Dessel, J. Genescà, J.M. Pericàs, M. Posch, A. Sánchez-Montalva, A.B. Estevez, À. Sánchez, A. Sanjuan, E. Sena, E. Granados, E. Arévalo de Andrés, F. Nuñez, G. Arteaga, G.P. Fuentes Ruiz, G. Fernández, J. Rivera-Esteban, J. Comella, J.A. Ramos-Quiroga, J. Genescà, J. Espinosa, J.M. Pericàs, L. Murcia, L. Cash-Gibson, M. de Valles Silvosa, M.F. Barroso de Sousa, O. Sánchez-Maroto Carrizo, P. Ibañez-Jiménez, S. Augustin, S. Perez-Hoyos, S. Rodríguez-Navarro, S. Muñoz-Martínez, S. Serres, S. Kalko, A. Michon, A. Ussi, B. Lydall, E. van de Ketterij, I. Quiles, T. Carapina, C. Kumaus, D. Ramazanova, E.L. Meyer, F. Koenig, M.B. Roig, M. Brunner, M. Posch, P. Krotka, S. Zehetmayer, C. Carton, E. Legius, A. Begum, C. Pariante, C. Worrell, G. Lombardo, L. Sforzini, M. Brown, N. Gullet, N. Amasi-Hartoonian, R. Ferner, M. Kose, A. Spitaleri, A. Ghodousi, C. Di Serio, D. Cirillo, F. Cugnata, F. Saluzzo, F. Benedetti, M.G. Scarale, M. Zini, P.M. Rancoita, R. Alagna, S. Poletti, B. Dhaenens, J. Van Der Lei, J. de Steenwinkel, M. Moinat, R. Oostenbrink, W. Hoogendijk, M. Hölscher, N. Heinrich, C. Otte, C. Potratz, D. Zocholl, E. Kulakova, F. Tacke, J. Brasanac, J. Leubner, M. Krajewska, M.M. Freitag, S. Gold, T. Zoller, W.R. Chae, C. Daniel, L. Kara, M. Vaterkowski, N. Griffon, P. Wolkenstein, R. Pais, V. Ratziu, D. Voets, C. Maes, D. Kalra, G. Thienpoint, J. Deckerck, N. Lea, P. Singleton, K. Viele, P. Jacko, S. Berry, T. Parke, A. Michon, B. Aydin, C. Kubiak, J. Demotes, K. Ueda, M. Matei, S. Contrino, C. Röhl, E. Cordero, F. Greenhalgh, H. Jarke, J. Angelova, M. Boudes, S. Dressler, V. Strammiello, Q. Anstee, I. Gutierrez-Ibarluzea, M. Otte, N. Heimbach, B. Hofner, C. Burgwinkel, H. Kaestel, K. Hees, Q. Nguyen, D. Prieto-Alhambra, E.H.(. Tan, M. Raviglione, P. de Colombani, S. Villa, E. Maron, G. Evans, A.J. Savitz, A. Van Dessel, A. Duca, A. Kaminski, B. Wouters, B. Porter, C. Charron, C. Spiertz, C. Zizzamia, D. Millar, D. Hasselbaink, D. Orr, D. Kesters, E. Hubin, E. Davies, E. Didden, G. Guz, E. Verstraete, G. Mao, G. Capuano, H. Martynowicz, H. De Smedt, I. Larsson, I. Bruegelmans, I. Coste, J.M. Gonzalez Moreno, J. Niewczas, J. Xu, K. Rombouts, K. Woo, K. Wuyts, K. Hersh, K. Oldenburg, L. Zhang, M. Schmidt, M. Szuch, M. Todorovic, M. Mangelaars, M. Grewal, M. Sandor, N. Di Prospero, P. Van Houten, P. Minnick, P. Bastos, R. Patrizi, S. Morello, S. De Wilde, T. Sun, T. Kline, T. de Marez, T. Mielke, T. Reijns, V. Popova, Y. Flossbach, Y. Tymofyeyev, Z. De Groote, A. Sverdlov, A. Bobirca, A. Krause, C. Bobrica, D. Heintz, D. Magirr, E. Glimm, F. Baffert, F. Castiglione, F. Caruso, F. Patalano, F. Bretz, G. Heimann, I. Carbarns, I. Rodríguez, I. Ratescu, L. Hampson, M. Pedrosa, M. Hark, P. Mesenbrink, S.H. Penna, S. Bergues-Lang, S. Baltes-Engler, T. Arsiwala, V.J. Mondragon, H. Guo, J.L. Da Costa, C. Burman, G. Kirk, A. Aaes-Jørgensen, J. Dirach, M.S. Kjær, A. Martin, D. Hristov, F. Rousseaux, N. Hittel, R. Dornheim, D. Evans, N. Sykes, C. Couvert, C. Leuven, L. Notelet, M. Gidh-Jain, M. Jouannin, N. Ammour, S. Pierre, V. Haufe, Y. Dong, C. Dubanchet, N. de Préville, T. Baltauss, Z. Jian, S. Shnider, T. Bar-El, A. Bakker, M. Nievo, U. Iloeje, A. Conradie, E. Auffarrth, L. Lombard, M. Benhayoun, M. Olugbosi, S.S. Seidel, B. Gumí, C.G. Guzmán, E. Molero, G. Pairó, N. Machin, R. Cardelús, S. Ramasastry, S. Pelzer, A. Kremer, E. Lindfors, C. Lynch. - In: ECLINICALMEDICINE. - ISSN 2589-5370. - 67:(2024 Jan), pp. 102384.1-102384.12. [10.1016/j.eclinm.2023.102384]

Current state-of-the-art and gaps in platform trials: 10 things you should know, insights from EU-PEARL

A. Spitaleri
Membro del Collaboration Group
;
S. Villa
Membro del Collaboration Group
;
2024

Abstract

Unlabelled: Platform trials bring the promise of making clinical research more efficient and more patient centric. While their use has become more widespread, including their prominent role during the COVID-19 pandemic response, broader adoption of platform trials has been limited by the lack of experience and tools to navigate the critical upfront planning required to launch such collaborative studies. The European Union-Patient-cEntric clinicAl tRial pLatform (EU-PEARL) initiative has produced new methodologies to expand the use of platform trials with an overarching infrastructure and services embedded into Integrated Research Platforms (IRPs), in collaboration with patient representatives and through consultation with U.S. Food and Drug Administration and European Medicines Agency stakeholders. In this narrative review, we discuss the outlook for platform trials in Europe, including challenges related to infrastructure, design, adaptations, data sharing and regulation. Documents derived from the EU-PEARL project, alongside a literature search including PubMed and relevant grey literature (e.g., guidance from regulatory agencies and health technology agencies) were used as sources for a multi-stage collaborative process through which the 10 more important points based on lessons drawn from the EU-PEARL project were developed and summarised as guidance for the setup of platform trials. We conclude that early involvement of critical stakeholder such as regulatory agencies or patients are critical steps in the implementation and later acceptance of platform trials. Addressing these gaps will be critical for attaining the full potential of platform trials for patients. Funding: Innovative Medicines Initiative 2 Joint Undertaking with support from the European Union's Horizon 2020 research and innovation programme and EFPIA.
Adaptive designs; Clinical research; Integrated research platform; Master protocols; Patient-centred;
Settore BIO/10 - Biochimica
gen-2024
Article (author)
File in questo prodotto:
File Dimensione Formato  
1-s2.0-S2589537023005618-main.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 392.93 kB
Formato Adobe PDF
392.93 kB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/1041651
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 1
  • ???jsp.display-item.citation.isi??? 1
social impact